The general partner of CompuGroup Medical SE & Co. KGaA (the “Company”) (ISIN: DE000A288904 | WKN: A28890) announces that today it has once again reviewed the guidance for the current financial year 2022 and, due to the postponement of projects (in particular of the PTV5-update) into the financial year 2023, adjusted the guidance for the adjusted operative earnings (EBITDA, as defined in the 2021 annual report of the Company) to EUR 220 million to EUR 240 million (previously EUR 240 million to EUR 260 million), and for the adjusted earnings per share (as defined in the 2021 annual report of the Company) to EUR 1.70 to EUR 1.90 (previously EUR 1.90 to EUR 2.10). The free cashflow (as defined in the 2021 annual report of the Company) is now forecasted to be in a range between EUR 40 million and EUR 70 million (previously over EUR 100 million). The Company now expects revenues for the current financial year 2022 to be in a range between EUR 1,100 million and EUR 1,130 million (previously EUR 1,100 million to EUR 1,150 million). Preliminary revenues for the first nine months of the current financial year 2022 are expected to be EUR 802 million with adjusted operating earnings (EBITDA, as defined in the 2021 annual report of the Company) of EUR 166 million.

CompuGroup Medical SE & Co. KGaA will publish its results for the first nine months of the current financial year 2022 as scheduled on November 3, 2022.